VEGFA and neoplasm: Bevacizumab is a monoclonal antibody that inhibits the vascular endothelial growth factor and is mainly used for metastatic cancer treatment, with the mechanism to inhibit the mitosis of tumor vascular endothelial cells and angiogenesis by blocking or reducing the binding of the vascular endothelial growth factor to its corresponding receptor.